[VEEV] Veeva: Q3 FY2027 Preview on Vault CRM Migration and Growth
![Editorial illustration for [VEEV] Veeva: Q3 FY2027 Preview on Vault CRM Migration and Growth](/_next/image?url=https%3A%2F%2Fdqmfnqdikmmdqihqtktm.supabase.co%2Fstorage%2Fv1%2Fobject%2Fpublic%2Farticle-images%2Fnewsroom%2Fdg_b585267f93e570ec%2Fe5e08b229454992e06a6b533609076092ee5eee1dcaee841a60ca985f1c6453a.jpg&w=3840&q=75&dpl=dpl_2cCASAreAudiz4bNx5tKbQ5L25Q9)
Summary
Veeva grew Q2 FY2027 revenue 18% to $928.0 million with a 44.8% non-GAAP margin; Q3 tests whether Commercial subscriptions hold 13% growth through the Vault CRM migration.
Veeva sells industry cloud software to pharmaceutical and biotech companies, which use it to manage sales-rep visits, clinical trials, regulatory submissions, drug safety and manufacturing quality[1]. The company has announced that it will report results for its fiscal third quarter 2027 (three months ended October 31, 2026) after the U.S. market close on 2026-12-03[2], a report that will test how Veeva's Vault CRM migration is affecting subscription growth. In the most recent disclosed quarter, fiscal Q2 2027 (ended July 31, 2026), total revenue was $928.0 million, up 18% year over year, subscription revenue was $766.8 million, up 16%, non-GAAP operating income was $415.9 million and non-GAAP diluted EPS was $2.35, up from $1.99 a year earlier[3]. On August 26 the company guided third-quarter total revenue to $932-935 million, non-GAAP operating income to $417-420 million and non-GAAP EPS to $2.33-2.34[4]. A November 6 filing shows that CFO Brian Van Wagener broke the third-quarter outlook down at the company's Investor Day into subscription revenue of about $782 million and services revenue of $150-153 million, and said the company expects third-quarter results to meet or exceed guidance[5]. Analyst consensus compiled by Drillr as of November 18 stands at $935.2 million in third-quarter revenue (15 analysts, range $934.2-936.1 million) and EPS of $2.34 (16 analysts, range $2.33-2.36), which puts revenue near the top of guidance and EPS level with its upper end[6].
Three things matter most in this report. The first is whether Commercial Solutions subscriptions can hold roughly 13% year-over-year growth: this revenue is built around CRM, its growth recovered from 10.6% in the first quarter to 13.0% in the second, and Veeva is moving its CRM customers off the Salesforce platform onto its own Vault CRM while some large drugmakers have used the moment to switch to Salesforce[7][8], so the growth rate will show whether migration-era churn is starting to reach revenue. The second is whether R&D and Quality Solutions subscriptions can stay above 18.5%: they grew 19.1% and 19.3% in the first two quarters, which management credits to early-cycle products in clinical data, drug safety and lab systems[7][9], and because this line already accounts for 54% of subscription revenue, its pace largely sets the company's overall growth[1]. The third is whether non-GAAP operating income can again clearly beat the $417-420 million guide: the second quarter came in about $21 million above the top of guidance, but the services gross margin fell from 33.4% a year earlier to 31.5%[10], and this quarter's cost structure will show whether services expansion and AI spending are beginning to erode a margin of about 45%.
Company Background and Business Structure
Veeva is a cloud software company that serves only the life sciences industry; it generated $3.195 billion in revenue in fiscal 2026 (ended January 31, 2026)[11] and ended the year with 1,552 customers, including 767 Commercial Solutions customers and 1,196 R&D and Quality Solutions customers[1]. The company groups its products into four clouds: revenue from Development Cloud and Quality Cloud is reported as R&D and Quality Solutions, and revenue from Commercial Cloud and Data Cloud is reported as Commercial Solutions[1]. Brian Van Wagener is chief financial officer[12], and the company discloses subscription and services revenue separately for these two product groups[11].
The two product groups serve different departments inside a drugmaker. Commercial Solutions serves sales and marketing teams; its core is CRM, the system that records sales-rep visits and compliance information, alongside data products and advertising measurement products such as Crossix, and it produced $1.258 billion in subscription revenue and $189 million in services revenue in fiscal 2026[11]. R&D and Quality Solutions serves research, regulatory, drug safety and manufacturing quality departments with products that include the electronic trial master file (eTMF), clinical trial management (CTMS), electronic data capture (EDC), electronic clinical outcome assessment (eCOA), randomization and trial supply management (RTSM), Safety, QualityDocs, QMS and laboratory information management (LIMS)[4][9]; it produced $1.427 billion in subscription revenue and $322 million in services revenue in fiscal 2026[11].
R&D and Quality is gaining weight in the mix, and the company expects that trend to continue. In fiscal 2026 Commercial and R&D and Quality contributed 47% and 53% of subscription revenue; in the first half of fiscal 2027 the split was 46% and 54%, and their shares of total revenue were 44% and 56%[1]. In the second quarter, 60% of subscription revenue came from North America, 29% from Europe and 11% from other regions, mainly Asia Pacific[13]. Customer concentration is meaningful: in each of fiscal 2024 through 2026, the top 10 customers accounted for 28% of total revenue[14], or about $890 million on fiscal 2026 revenue, while many R&D application customers are smaller pre-commercial biotechs, some of which may never reach commercialization[1].
Growth comes mainly from existing customers using more products, followed by annual inflation price increases. Fiscal 2026 subscription revenue rose $400 million, with $247 million from R&D and Quality and $153 million from Commercial, and the 10-K attributes both increases primarily to expanding use by existing customers and, to a lesser extent, the annual inflation adjustment[15]. Of the $108 million increase in subscription revenue in fiscal Q2 2027, R&D and Quality contributed $68 million and Commercial $40 million, with the same drivers cited[13]. Services revenue comes from implementation and business consulting, as Veeva uses its own consultants to bring customers live and migrate their systems[15][13].
Financial History and Current Position
On an annual basis, Veeva has grown revenue by about 16% for two straight years. Total revenue rose from $2.364 billion in fiscal 2024 to $2.747 billion in fiscal 2025 and $3.195 billion in fiscal 2026; fiscal 2026 subscription revenue was $2.684 billion, up about 17.5%, including R&D and Quality subscriptions of $1.427 billion, up about 20.9%, and Commercial subscriptions of $1.258 billion, up about 13.8%, while services revenue was $511 million[11].
Profit and cash flow have grown considerably faster than revenue. Fiscal 2026 GAAP operating income was $916 million; adding back $473 million of stock-based compensation, $14.1 million of intangible amortization and $30.6 million of litigation settlement-related charges gives non-GAAP operating income of $1.434 billion, a margin of about 44.9%, compared with $1.152 billion a year earlier[16]. GAAP net income for the year was $909 million, non-GAAP diluted EPS rose from $6.60 to $8.10, and operating cash flow rose from $1.090 billion to $1.415 billion[16].
The first half of fiscal 2027 extended that pattern, and every second-quarter metric beat the company's guidance. Second-quarter total revenue was $928.0 million, up 18%, subscription revenue was $766.8 million, up 16%, GAAP operating income was $275.0 million, up 40%, and non-GAAP operating income was $415.9 million, up 18%[3]; on June 3 the company had guided the quarter to revenue of $902-905 million and non-GAAP operating income of $392-395 million[17]. Second-quarter services revenue was $161.2 million, up about 24% from $129.9 million a year earlier, and first-half total revenue was $1.811 billion, up about 17%[7].
Veeva's balance sheet is dominated by cash, and capital returns run through buybacks. As of July 31, 2026, cash, cash equivalents and short-term investments totaled $7.2 billion; first-half operating cash flow was $1.366 billion versus $1.116 billion a year earlier, and over the same period the company repurchased and retired about 2.66 million shares for about $467 million, leaving $1.4 billion of repurchase authorization[18]. Second-quarter operating cash flow alone was $238.7 million, essentially flat with $238.4 million a year earlier[10], which means most first-half cash flow arrived in the first quarter. With second-quarter results the company updated full-year guidance to revenue of $3.682-3.687 billion, non-GAAP operating income of about $1.640 billion and non-GAAP EPS of about $9.21[4]; in June the first two figures had been $3.635-3.645 billion and about $1.610 billion[17].
Operating Model
Veeva's revenue splits into subscriptions and services, and subscriptions are the bulk and are recognized evenly over each contract term. In the second quarter subscriptions were about 83% of total revenue, with Commercial subscriptions of $347.4 million and R&D and Quality subscriptions of $419.4 million, alongside $161.2 million of services revenue[7]. Because subscription revenue is recognized ratably, a substantial majority of each quarter's subscription revenue comes from contracts signed in earlier periods, so a drop in new subscriptions in one quarter may not hit that quarter but can reduce revenue in later quarters[19]. CRM churn or the ramp of new R&D products therefore takes several quarters to show fully in subscription revenue; the company's third-quarter subscription outlook of about $782 million is roughly $15 million above the second quarter[5][7].
Profit depends on revenue mix and three groups of costs, and subscription and services margins differ sharply. In the second quarter the non-GAAP subscription gross margin was 86.6%, the services gross margin was 31.5% and the blended gross margin was 77.1%[10]; on a non-GAAP basis, cost of subscriptions was $102.4 million, cost of services $110.4 million, research and development $160.4 million, sales and marketing $96.1 million and general and administrative $42.8 million, leaving non-GAAP operating income of $415.9 million[20]. Subscription cost growth came mainly from computing infrastructure and data costs, which rose $12 million year over year in the second quarter and $32 million in the first half, while services cost growth came mainly from employee compensation, up $19 million in the second quarter[21]. A higher services share or lower consultant utilization therefore pulls down the overall margin, while AI computing costs flow through the subscription gross margin; GAAP operating income also absorbs stock-based compensation and other items, and the gap between GAAP and non-GAAP operating income was about $141 million in the second quarter[3].
Cash flow and profit are seasonally out of step, so a single quarter's cash flow cannot be compared directly with earnings. Veeva generally bills subscription orders at the start of the subscription period in annual or quarterly increments, and many large customers are billed quarterly, so deferred revenue at any single point does not fully reflect the annualized value of orders; the company says full-year subscription revenue guidance and normalized billings guidance are the best indicators of business momentum[22]. Of the $1.366 billion in first-half operating cash flow, only $238.7 million came in the second quarter[18][10], showing that annual billings are collected mostly in the first quarter, and buybacks were the main use of cash at about $467 million in the first half[18].
Industry and Competitive Position
Veeva's competitive position differs by product line, and CRM is where it has changed most. The 10-K states that Veeva's CRM competes primarily with Salesforce, which has developed a life sciences-specific CRM, and that IQVIA, which historically offered a competing CRM, has licensed its CRM software to Salesforce[23]. Salesforce has announced that certain large Veeva CRM customers have committed to its product, and a number of Veeva customers have said they intend to move to Salesforce[23][8]. On the other side, Vault CRM had more than 180 customers live as of August 26, including five top 20 biopharmas, and 12 of the top 20 biopharmas had committed to Vault CRM[12]; on the second-quarter call management said Lilly and Biogen had selected Vault CRM and that it is aiming for more than 70% long-term CRM share[24].
R&D, quality and data face a more fragmented set of rivals. IQVIA, Dassault Systèmes, OpenText, Oracle, Honeywell and others compete with certain Development Cloud and Quality Cloud applications, while the Data Cloud and Crossix compete with IQVIA, Ipsos, Definitive Health and smaller data analytics providers[23]. The advantage that the evidence supports is multi-product expansion on one platform: in the second quarter a large enterprise biopharma added EDC to its existing eTMF, CTMS and Study Startup products, Veeva Safety passed 100 customers, and Quality added more than 30 new customers[4]. The company does not disclose revenue by product, however, and the available material contains no competitor financials that allow a line-by-line comparison, so Veeva's share in each product line cannot be quantified.
AI is becoming a new competitive dimension, but it will not contribute meaningful revenue soon. Veeva is building Veeva Falcon, an agentic labor platform for clinical, regulatory and safety work, which had five early adopters as of August and is on track for initial go-lives in 2026; in the second quarter the company also acquired Copli and launched Falcon MLR to automate content reviews[4]. On the first-quarter call management said AI revenue will be immaterial for fiscal 2027 because the company is prioritizing product and customer success over near-term monetization, and that any AI-related margin effects are already in guidance[25].
Core Debates
Veeva must move its CRM customers off the Salesforce platform and onto its own Vault CRM before 2030, and some large drugmakers have used the moment to switch to Salesforce. Commercial subscription growth recovered to 13% in the second quarter, and 12 of the top 20 biopharmas have committed to Vault CRM. Can this subscription line keep growing at about 13% in the third quarter?
This question matters because CRM is the product Veeva was built on, and CRM customer losses take years to show up in revenue. Commercial Solutions made up about 44% of total revenue in the first half of fiscal 2027[1], and the top 10 customers account for 28% of total revenue[14]. Veeva's platform agreement with Salesforce expired on September 1, 2025, opening a wind-down period that runs to September 1, 2030[26]; customers can keep using the legacy system until their contracts end, so losing a top 20 biopharma affects a multi-year subscription base rather than a single quarter.
The current evidence shows growth recovering, but evidence of churn also exists. Commercial subscriptions were $347.4 million in the second quarter, up 13.0% from $307.5 million a year earlier, while the first quarter, derived by subtracting the second quarter from the first half, was $337.9 million, up 10.6%[7]; management called the second quarter CRM's best ever and said Commercial subscriptions still grew at a double-digit rate excluding Crossix[24]. Vault CRM live customers rose from more than 150 at the end of the first quarter to more than 180 in August, and top 20 commitments rose from 10 at the first-quarter report to 12, with management saying in the first quarter that four more decisions would come in 2027[17][12][9]. An alternative reading is that part of the recovery comes from acquisitions and Crossix: management explained in the first quarter that about $10 million of the $15 million increase in full-year Commercial subscription guidance came from the OSTRO acquisition[25], customers that have chosen Salesforce keep paying for legacy Veeva CRM until their contracts expire, and the 10-Q states that some customers have already said they will move to Salesforce[8].
In financial terms, CRM choices by the top 20 and smaller drugmakers first determine Vault CRM migrations and go-lives, which then feed Commercial subscription revenue through seat retention and added products, while customers that switch to Salesforce stop paying when their contracts end. What remains unresolved is how much of the 13% growth comes from non-CRM sources such as OSTRO and Crossix, and when payments from departing customers will start to stop in a concentrated way. Management sees the main opportunity to win back customers struggling with Salesforce implementations in 2027-2028[27], which is a possible upside but also means the CRM landscape will not settle before 2030.
The next items to watch are whether third-quarter Commercial subscription growth is at least 13%, whether Vault CRM live customers reach about 210, and whether top 20 commitments rise to 13 or more without any customer publicly switching to Salesforce. If Commercial subscription growth falls below 10%, the CRM base is loosening during the migration; if the remaining top 20 biopharmas choose Salesforce, the ceiling on this subscription line before 2030 drops.
Veeva's R&D and Quality subscriptions grew about 19% in each of the first two quarters, which management attributes to early-cycle products such as clinical data, drug safety and lab systems, yet it raised full-year guidance by only $5 million. Can growth hold at 18.5% or more in the third quarter rather than slipping toward the lower pace implied by guidance?
This question decides whether Veeva can sustain overall growth through the CRM migration. R&D and Quality already accounts for 54% of subscription revenue, and the company expects its share of both subscription and total revenue to keep rising[1]; of the $108 million increase in second-quarter subscription revenue, $68 million came from R&D and Quality[13]. If growth in this line slows noticeably, Commercial holding 13% would not be enough to support subscription growth of about 16%.
The current evidence supports continued strong growth, but management's full-year stance is cautious. R&D and Quality subscriptions were $419.4 million in the second quarter, up 19.3% from $351.7 million a year earlier, and $392.3 million in the first quarter, up 19.1%; R&D and Quality services revenue was $101.5 million in the second quarter, up 23.4%, and $196.7 million in the first half, up 23.0%[7]. In the second quarter a large enterprise biopharma selected EDC, Veeva Safety passed 100 customers and won its second top 20 biopharma for Safety Workbench, and Quality added more than 30 new customers[4]. Management said in the first quarter that R&D was outpacing full-year guidance by a few percentage points on the scaling of early-cycle products such as eCOA, RTSM, Safety and LIMS, yet it raised full-year revenue guidance by only $5 million at the time and described this as conservatism rather than a hidden headwind[9][25]. An alternative reading is that no large top 20 deals closed in the first quarter, which management attributed to timing[9], so growth may have come more from smaller biotechs and annual price increases; on the second-quarter call management also acknowledged that these new products are still at an early stage with shifting S-curves[24].
In financial terms, adoption of new applications by drugmakers' research, safety and quality departments adds customers, studies and users, and together with cross-selling of older products and annual price increases it lifts R&D and Quality subscription revenue; implementation services usually precede subscription go-lives, so strong services growth is a leading signal of subscription ramp. What remains unresolved is whether first-half growth of about 19% reflects a sustained ramp of early-cycle products or project and pricing effects concentrated in a few quarters. Falcon, the AI execution milestone for this business, is scheduled for initial go-lives in 2026[4], and management acknowledged in the second quarter that Veeva itself is the "rate limiter" in getting the product ready for early adopters[27].
The next items to watch are whether R&D and Quality subscription growth is at least 18.5%, whether R&D and Quality services revenue keeps growing above 20%, whether new top 20 EDC or Safety wins are disclosed, and whether any Falcon customer goes live in production. If R&D and Quality subscription growth falls below 16%, the ramp of early-cycle products is slowing; if Falcon's initial go-lives slip, the timeline for a new AI revenue line moves out.
Veeva is expanding its services team to handle CRM migrations and new product implementations while stepping up AI and data investment, and its non-GAAP services gross margin has fallen from 33.4% to 31.5%. Can third-quarter non-GAAP operating income again clear the $417-420 million guidance by a wide margin and keep the margin near 45%?
This question bears on whether Veeva's combination of high margins and growth can continue. Fiscal 2026 non-GAAP operating income was $1.434 billion, a margin of about 44.9%[16]; if margins fall during an investment phase, cost growth would offset the value of beating revenue guidance.
The current evidence shows a stable margin, but the cost structure is shifting. Second-quarter non-GAAP operating income was $415.9 million, about $21 million above the top of the $392-395 million guide, for a margin of about 44.8%, essentially level with about 44.7% a year earlier[3][17]; full-year guidance of about $1.640 billion implies a margin of about 44.5%[4]. Services revenue grew about 24%, but the non-GAAP services gross margin fell to 31.5% from 33.4% a year earlier, and to 30.5% from 33.5% for the first half, while the subscription gross margin rose to 86.6% from 86.2%[10], and computing infrastructure and data costs rose $12 million year over year in the second quarter[21]. Management said in the first quarter that the first quarter's margin of about 45% was an outlier driven by strong Crossix performance and shifted expenses, and it kept its full-year non-GAAP operating margin guidance of about 44% at that time[25]. An alternative reading is that margin stability rests on subscription price increases and sales expense leverage, with the cost of services expansion and AI investment concentrated in the second half: subtracting first-half non-GAAP operating income of $811.3 million from full-year guidance leaves about $829 million for the second half[20][4], which corresponds to a lower margin than the first half.
In financial terms, the mix of subscriptions and services, consultant utilization, computing and data costs, and R&D and sales investment together set the non-GAAP operating margin, which then flows through to non-GAAP EPS. Second-quarter non-GAAP cost of services rose about 27.7% year over year, faster than services revenue growth of about 24%[20][7], showing that services expansion is pulling that margin down, while the subscription gross margin is still improving. What remains unresolved is whether higher second-half spending will take the margin from about 45% down to the level implied by guidance, and whether the services gross margin has already bottomed.
The next items to watch are whether third-quarter non-GAAP operating income reaches at least about $430 million, where services revenue lands against the $150-153 million guide and what services gross margin it carries, and whether the subscription gross margin holds above 86.5%. If non-GAAP operating income falls below the low end of guidance, spending has run ahead of plan; if the services gross margin falls below 29%, rapid services growth is diluting profit.
Risks and Falsifiers
The first risk is early termination of the Salesforce platform wind-down. The wind-down runs from September 1, 2025 to September 1, 2030, during which Veeva cannot sell applications on the Salesforce platform to new customers, and seats for customers existing on September 1, 2025 cannot exceed 150% of their use on that date, while Salesforce may terminate the wind-down early in certain circumstances, including a material breach by Veeva[26]. Revenue from customers still on legacy Veeva CRM sits in Commercial subscriptions, which were $1.258 billion in fiscal 2026[11]; if the wind-down ended early, migrations would have to accelerate, raising services costs and churn risk at the same time. As long as migration proceeds on schedule and the company discloses no dispute with Salesforce, this risk has not materialized.
The second risk is customer concentration and drugmaker budgets. The top 10 customers account for 28% of total revenue[14], so mergers, layoffs or R&D budget cuts at large drugmakers would directly reduce seats and projects, and a meaningful share of the 1,196 R&D application customers are early-stage pre-commercial biotechs whose survival depends on the funding environment[1]. The exposure is roughly $890 million of annual revenue from the top 10 customers plus R&D and Quality subscriptions. If the 10-Q continues to attribute subscription growth to expanding use by existing customers and customer counts keep rising[13], this risk has not yet appeared.
The third risk is large customers switching to Salesforce. Salesforce has licensed IQVIA's CRM and launched a life sciences CRM, and some large Veeva CRM customers have committed to switch[23][8]; these customers keep paying until their contracts end, so the loss shows up in Commercial subscriptions with a lag. The financial exposure is $1.258 billion of fiscal 2026 Commercial subscriptions and top 10 customers representing 28% of revenue. If top 20 Vault CRM commitments rise to 13 or more while Commercial subscriptions keep growing at a double-digit rate, concern about this risk would ease[12].
The fourth risk is AI replacing seat-based applications. Agentic AI could reduce drugmaker headcount in clinical, safety and regulatory roles and therefore the number of user-billed seats; on the second-quarter call management acknowledged that agentic labor is non-deterministic and requires robust guardrails and human-in-the-loop protocols[27], and in the first quarter it said AI revenue would be immaterial this fiscal year[25]. R&D and Quality subscriptions were $1.427 billion in fiscal 2026 and $419.4 million in the second quarter[11][7], and a lag between replacement and new revenue could depress this line's growth. If Falcon contracts priced per document or per case are signed while R&D and Quality subscriptions keep growing above 18%, replacement is not outrunning new revenue.
The fifth risk is AI computing cost. Inference compute for Falcon and Vault AI rises with usage, and management has said the effect is immaterial this fiscal year and already included in guidance[25]. Second-quarter non-GAAP cost of subscriptions was $102.4 million[20], and computing and data costs rose $12 million year over year[21]; on second-quarter subscription revenue of $766.8 million, each 1-point drop in subscription gross margin would cut quarterly profit by about $7.7 million. If the subscription gross margin stays above 86.5% and non-GAAP operating income keeps beating guidance, this risk has not yet reached the income statement.
What to Watch Next
- Commercial subscriptions during the CRM migration: whether third-quarter growth is at least 13%, against $347.4 million and 13.0% in the second quarter and 10.6% in the first; growth below 10% would mean the CRM base is loosening.
- Vault CRM adoption: whether live customers reach about 210 from more than 180 and top 20 commitments rise to 13 or more from 12; remaining top 20 biopharmas choosing Salesforce would lower the ceiling before 2030.
- R&D and Quality subscriptions: whether growth is at least 18.5%, against $419.4 million and 19.3% in the second quarter and 19.1% in the first; growth below 16% would indicate the early-cycle ramp is slowing.
- R&D and Quality services, EDC and Safety wins, and Falcon: whether services growth stays above 20% from $101.5 million and 23.4%, and whether Falcon, with five early adopters, goes live this year; a delay would push out the AI revenue timeline.
- Non-GAAP operating income: whether it reaches at least about $430 million, against $415.9 million and 44.8% in the second quarter and third-quarter guidance of $417-420 million; a result below the low end would mean spending ran ahead of plan.
- Services and subscription gross margins: whether the subscription margin holds above 86.5% from 86.6%, and where services revenue lands against the $150-153 million guide with a 31.5% services margin as the baseline; a services margin below 29% would mean growth is diluting profit.
Conclusion
Veeva's business runs on two subscription curves: CRM-centered Commercial subscriptions growing about 13% during the migration and R&D and Quality subscriptions growing about 19% on the ramp of early-cycle products, which together support subscription growth of about 16% and a non-GAAP operating margin of about 45%[7][3]. The company's finances are strong, with $7.2 billion of cash and short-term investments at the end of July 2026 and $1.366 billion of first-half operating cash flow, of which about $467 million went to buybacks[18]. The central unresolved relationships are when and how heavily CRM losses to Salesforce will reach Commercial subscriptions, whether high R&D and Quality growth can continue while guidance stays conservative, and whether services expansion and AI investment will pull the margin down from about 45%.
Independent outside interpretation published since the second-quarter report is scarce. Between the August 26, 2026 second-quarter report and November 19, Drillr's broker research library contained no Veeva reports, and related news consisted mostly of product launches and customer wins; the post-earnings articles available online were mostly call summaries or blog quick takes whose original text could not be verified word for word, and none met the standard for an independent outside view. No attributable outside interpretation can therefore be summarized at this point, which leaves readers to judge the third-quarter report against company guidance, filed results and the figures Drillr compiles, and this coverage gap is itself worth noting.
The combination that would materially strengthen the current understanding is third-quarter Commercial subscription growth of at least 13%, Vault CRM live customers approaching 210, and more top 20 commitments with no new public switch; R&D and Quality subscription growth of at least 18.5% with Falcon's first customers going live on schedule; and non-GAAP operating income clearly above $420 million with the subscription gross margin holding above 86.5%. Conversely, Commercial subscription growth below 10%, R&D and Quality growth below 16%, or non-GAAP operating income below the low end of guidance with a services gross margin under 29% would weaken the view that Veeva can sustain mid-teens growth at a margin of about 45% through the CRM migration.
Sources
[1] VEEV 10-Q filed 2026-08-27 · product categories, mix and customer counts · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[2] Veeva announcement 2026-11-12 · Q3 FY2027 results date · 2026-11-12 · press release · PR Newswire · https://www.prnewswire.com/news-releases/veeva-to-release-fiscal-2027-third-quarter-results-on-december-3-2026-302938353.html
[3] VEEV 8-K filed 2026-08-26 · Q2 FY2027 results · 2026-08-26 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=8-K
[4] VEEV 8-K filed 2026-08-26 · Q3 and FY2027 guidance, Falcon and R&D highlights · 2026-08-26 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=8-K
[5] VEEV 8-K filed 2026-11-06 · Investor Day Q3 FY2027 guidance slide · 2026-11-06 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=8-K
[6] Drillr analyst_financial_estimates (updated 2026-11-18) · VEEV quarter ending 2026-10-31 and fiscal year ending 2027-01-31 · 2026-11-18 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private
[7] VEEV 10-Q filed 2026-08-27 · revenues by product Q2 and first half FY2027 · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[8] VEEV 10-Q filed 2026-06-05 · CRM competition and customer moves to Salesforce · 2026-06-05 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=10-Q
[9] VEEV Q1 FY2027 earnings call 2026-06-03 · CRM, R&D and services commentary · 2026-06-03 · earnings-call · https://ir.veeva.com
[10] VEEV 8-K filed 2026-08-26 · non-GAAP gross margin reconciliation · 2026-08-26 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=8-K
[11] VEEV 10-K filed 2026-03-20 · revenues by product fiscal 2026 · 2026-03-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/
[12] VEEV 8-K filed 2026-08-26 · Vault CRM highlights · 2026-08-26 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=8-K
[13] VEEV 10-Q filed 2026-08-27 · Q2 FY2027 revenue drivers · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[14] VEEV 10-K filed 2026-03-20 · top 10 customer concentration · 2026-03-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/
[15] VEEV 10-K filed 2026-03-20 · fiscal 2026 revenue growth drivers · 2026-03-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/
[16] VEEV 10-K filed 2026-03-20 · fiscal 2026 non-GAAP reconciliation and cash flow · 2026-03-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/
[17] VEEV 8-K filed 2026-06-03 · Q1 FY2027 highlights and Q2 guidance · 2026-06-03 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052&type=8-K
[18] VEEV 10-Q filed 2026-08-27 · liquidity, cash flow and repurchases · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[19] VEEV 10-Q filed 2026-08-27 · ratable recognition and services volatility · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[20] VEEV 10-Q filed 2026-08-27 · adjusted operating income by cost line · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[21] VEEV 10-Q filed 2026-08-27 · cost of revenue drivers · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[22] VEEV 10-Q filed 2026-08-27 · billing pattern and deferred revenue caveat · 2026-08-27 · 10-Q · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/
[23] VEEV 10-K filed 2026-03-20 · competition · 2026-03-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/
[24] VEEV Q2 FY2027 earnings call 2026-08-26 · CRM, Falcon and growth commentary · 2026-08-26 · earnings-call · https://ir.veeva.com
[25] VEEV Q1 FY2027 earnings call 2026-06-03 · guidance, OSTRO and AI revenue · 2026-06-03 · earnings-call · https://ir.veeva.com
[26] VEEV 10-K filed 2026-03-20 · Salesforce platform wind-down · 2026-03-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/
[27] VEEV Q2 FY2027 earnings call 2026-08-26 · risks and Q&A · 2026-08-26 · earnings-call · https://ir.veeva.com